H. Lundbeck A/S's latest marketcap:
As of 06/26/2025, H. Lundbeck A/S's market capitalization has reached $5.42 B. According to our data, H. Lundbeck A/S is the 3081th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 5.42 B |
| Revenue (ttm) | 3.59 B |
| Net Income (ttm) | 514.42 M |
| Shares Out | 991.23 M |
| EPS (ttm) | 0.52 |
| Forward PE | 6.88 |
| Ex-Dividend Date | 03/27/2025 |
| Earnings Date | 08/20/2025 |
H. Lundbeck A/S's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/26/2025 | kr5.42 B | -11.81% | 3081 |
| 12/30/2024 | kr39.42 B | 24.27% | 2806 |
| 12/29/2023 | kr31.72 B | 24.72% | 3000 |
| 12/30/2022 | kr25.43 B | 3486 |
Company Profile
About H. Lundbeck A/S
H. Lundbeck A/S is a global pharmaceutical company specializing in the research, development, manufacturing, and commercialization of treatments for psychiatric and neurological disorders. Headquartered in Valby, Denmark, the company operates across Europe, the United States, and international markets.
Key Products
- Abilify Maintena/Abilify Asimtufii – For schizophrenia and bipolar I disorder in adults.
- Brintellix/Trintellix – Treats depressive disorders.
- Rexulti/Rxulti – Used for major depressive disorder and schizophrenia.
- Vyepti – Prevents migraines.
- Cipralex/Lexapro – Addresses depression.
- Northera – Treats symptomatic neurogenic orthostatic hypotension.
- Onfi – For epilepsy.
- Sabril – Used for refractory complex partial seizures and infantile spasms.
- Ebixa – Treats dementia.
- Azilect – For Parkinson’s disease.
- Xenazine – Addresses chorea.
- Deanxit – Treats depression.
- Cipramil – For depression and anxiety.
- Cisordinol – Used for psychosis.
Pipeline Developments
- Eptinezumab – In phase 3 for migraine prevention and cluster headache.
- Lu AG09222 – Phase 2 trial for migraine prevention.
- Lu AG13909 – Phase 1 trial for neurohormonal dysfunctions.
- Brexpiprazole – Investigated for post-traumatic stress disorder.
- Lu AF28996 – Phase 1 trial for Parkinson’s disease.
- MAGLi Program – Phase 1 trial for neurology.
- Bexicaserin – Phase 3 trial for developmental and epileptic encephalopathies.
- Amlenetug – Phase 3 trial for synucleinopathies.
- Lu AG22515 – Phase 1 trial for neurology.
Founded in 1915, H. Lundbeck A/S remains committed to advancing treatments for complex brain disorders.
Frequently Asked Questions
-
What is H. Lundbeck A/S's (CPH-HLUN.B) current market cap?As of 06/26/2025, H. Lundbeck A/S (including the parent company, if applicable) has an estimated market capitalization of $5.42 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does H. Lundbeck A/S (CPH-HLUN.B) rank globally by market cap?H. Lundbeck A/S global market capitalization ranking is approximately 3081 as of 06/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.